BOLERO-1 reports HER2-positive breast cancer latest PFS data
Visit http://www.ecancer.org for more. Prof Hurvitz (University of California, Los Angeles, USA) talks to ecancertv at SABCS 2014 about the results of a phase III trial which looked at the effects of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2 advanced breast cancer.
Visit http://www.ecancer.org for more. Prof Hurvitz (University of California, Los Angeles, USA) talks to ecancertv at SABCS 2014 about the results of a phase III trial which looked at the effects of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2 advanced breast cancer.